• Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. & Abramson, J.S. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for burkitt's lymphoma: a retrospective analysis. Annals of Oncology, 22, 18591864.
  • Cortes, J., Thomas, D., Rios, A., Koller, C., O'Brien, S., Jeha, S., Faderl, S. & Kantarjian, H. (2002) Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer, 94, 14921499.
  • Dunleavy, K., Little, R.F., Pittaluga, S., Grant, N., Wayne, A.S., Carrasquillo, J.A., Steinberg, S.M., Yarchoan, R., Jaffe, E.S. & Wilson, W.H. (2010) The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood, 115, 30173024.
  • Galicier, L., Fieschi, C., Borie, R., Meignin, V., Daniel, M.T., Gerard, L. & Oksenhendler, E. (2007) Intensive chemotherapy regimen (LMB86) for st jude stage IV AIDS-related burkitt lymphoma/leukemia: a prospective study. Blood, 110, 28462854.
  • Lim, S.T., Karim, R., Nathwani, B.N., Tulpule, A., Espina, B. & Levine, A.M. (2005) AIDS-related burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. Journal of Clinical Oncology, 23, 44304438.
  • Montoto, S., Wilson, J., Shaw, K., Heath, M., Wilson, A., McNamara, C., Orkin, C., Nelson, M., Johnson, M., Bower, M. & Cwynarski, K.. (2010) Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated burkitt's lymphoma. AIDS (London, England), 24, 851856.
  • Di Nicola, M., Carlo-Stella, C., Mariotti, J., Devizzi, L., Massimino, M., Cabras, A., Magni, M., Matteucci, P., Guidetti, A., Gandola, L. & Gianni, A.M. (2004) High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for burkitt's lymphoma in adults. British Journal of Haematology, 126, 815820.
  • Oriol, A., Ribera, J.M., Bergua, J., Gimenez Mesa, E., Grande, C., Esteve, J., Brunet, S., Moreno, M.J., Escoda, L., Hernandez-Rivas, J.M. & Hoelzer, D. (2008) High-dose chemotherapy and immunotherapy in adult burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer, 113, 117125.
  • Rodrigo, J.A., Hicks, L.K., Cheung, M.C., Song, K.W., Ezzat, H., Leger, C.S., Boro, J., Montaner, J.S., Harris, M. & Leitch, H.A. (2012) HIV-associated burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Advances in Hematology, 2012, 735392.
  • Sparano, J.A., Lee, J.Y., Kaplan, L.D., Levine, A.M., Ramos, J.C., Ambinder, R.F., Wachsman, W., Aboulafia, D., Noy, A., Henry, D.H., Von Roenn, J., Dezube, B.J., Remick, S.C., Shah, M.H., Leichman, L., Ratner, L., Cesarman, E., Chadburn, A. & Mitsuyasu, R. & AIDS Malignancy Consortium. (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-hodgkin lymphoma. Blood, 115, 30083016.